Company ProfilePremium

BioWorks Inc.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
BioWorks Inc. - Company showcase

Year Founded & Workforce

1993

950 Employees

BioWorks Inc. logo

BioWorks Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BioWorks Inc. Overview

BioWorks, Inc. is a North American developer, manufacturer and marketer of biological crop protection and plant health inputs. Its base is greenhouse ornamentals, nursery, controlled-environment vegetables, cannabis and, increasingly, outdoor specialty crops. The company grew out of Cornell University Trichoderma research and built its franchise on the RootShield biofungicide family. It has since broadened into foliar disease control, bioinsecticides, beneficial nematodes, soaps and oils, a bioherbicide, and a fast-growing plant nutrition and biostimulant line. BioWorks sells through horticultural distributors and supports growers with a technical field team, which is a real differentiator in a category where correct use determines results. Since July 2023 it has belonged to Biobest/BioFirst Group, the biologicals arm of Floridienne. It now serves as the group's North American biopesticide manufacturing hub, with plans to export Trichoderma output to Brazil and Europe. Management's stated ambition is USD 100 million of BioWorks revenue by 2034.


What the company does. BioWorks formulates, produces, registers and sells biologically based inputs that prevent or control plant diseases and insect, mite and nematode pests, plus products that support plant nutrition and stress tolerance. Its current self-description (press releases, 2026) is a leading provider of biological crop protection and plant health solutions. The "About BioWorks" boilerplate in the August 2026 BIOTROP release calls it a North American leader in biological solutions for horticulture, greenhouse and specialty crop markets, supplying biopesticides and biostimulants that reduce reliance on conventional chemistry. There is no annual report to quote from, because the company does not publish one.

Business model. The model is a branded specialty-input manufacturer with a technical-sales overlay. Three elements define it:

  1. Proprietary and licensed actives. The core asset is the Cornell-derived Trichoderma harzianum strain T-22 (RootShield), later combined with T. virens G-41 (RootShield PLUS). Several other products rely on third-party actives or strains (for example CEASE, based on Bacillus subtilis QST 713). Licensing terms are not disclosed.

  2. In-house manufacturing and formulation. The Victor facility (over 55,000 sq ft) combines production, R&D, warehouse and office functions (Biobest releases, 2023).

  3. Distributor channel. Products reach growers through horticultural and agricultural distributors in the US, Canada and Mexico; the website lists "Where to Buy" directories for all three. From September 2025, European distributors buy BioWorks-branded products directly from BioWorks (New AG International, 19 Sep 2025).

Revenue model. Revenue is product sales. There is no disclosed subscription, licensing or service revenue. Technical support, webinars and program design are bundled with product rather than billed. The product/service/licensing mix is not publicly disclosed.

Value chain position. BioWorks sits between strain and technology originators (universities, licensors, sister company BIOTROP) and distributors. It carries the regulatory burden (US EPA FIFRA registrations, state registrations, PMRA in Canada, OMRI listings for organic use), which is a meaningful barrier to entry.

Customers and end-markets. The website's own segmentation of grower types is: indoor horticulture, indoor vegetable, nursery, outdoor specialty agriculture, and cannabis. The February 2026 strategy statement names grapes, almonds and berries as open-field targets.

Independent characterization. BioWorks is a small, technically credible niche player with a strong brand in US greenhouse ornamentals. For three decades it was run as an independent company with steady growth (RBJ reported revenue growth of 27% in 2010, 23% in 2011 and 10% in 2012; a 2018 Western Growers profile described double-digit annual growth). Its strategic meaning has changed since 2023. It is now the North American horticulture channel and Trichoderma production site for a group whose centre of gravity is Brazilian row-crop biologicals. That brings a much larger technology pipeline, and the 2026 launch cadence shows it. It also means BioWorks' priorities are now set in Brazil and Belgium, not in Victor.

Strategy

Stated strategy. Management's February 2026 statement set out six priorities for the next phase (paraphrased from the release):

  1. Strengthen leadership in horticulture and greenhouse crops.

  2. Expand into open-field specialty crops such as grapes, almonds and berries.

  3. Accelerate revenue growth through disciplined commercial execution.

  4. Broaden national sales coverage across the United States.

  5. Scale operations to support a larger portfolio.

  6. Bring BIOTROP's proprietary biological technologies to the US market.

Chris Rose framed the transition as "an acceleration", not a reset.

Initiatives, last 24 months.

Medium-term targets.

Sustainability commitments. None are published by BioWorks. At group level Biobest stated an aim of CO2 neutrality from 2026 (Floridienne Annual Report 2023). No cost-reduction programs with targets have been disclosed.

Products & Services

The catalogue below follows the US product navigation on bioworksinc.com as of September 2026. Pricing is set through distributors and is not publicly disclosed for any product.

Disease Control

ProductDescription and capabilityTarget customerLaunch / status
RootShield (WP, Granules)Preventive biofungicide for root diseases based on Trichoderma harzianum strain T-22; colonizes roots. Founding product from Cornell technologyGreenhouse, nursery, vegetable transplant growersTrademark filed 1996; flagship
RootShield PLUS (WP, Granules)Two-strain formulation adding Trichoderma virens G-41 for broader root pathogen coverage, including warm-season PythiumSame, plus nursery container production (2026 boxwood trial with Everde Growers)Established by 2018
BotryStop WPBiofungicide for Botrytis and related foliar and flower pathogens (Ulocladium oudemansii U3; analyst knowledge)Ornamentals, berries, grapes, cannabisPre-2023
CEASEBroad-spectrum foliar and soil biofungicide and bactericide based on Bacillus subtilis QST 713; OMRI listed; tank-mix partner with MilStopGreenhouse ornamentals and vegetablesLong-standing
MilStop SPPotassium bicarbonate contact fungicide, curative on powdery mildew; OMRI listedGreenhouse, nursery, cannabisLong-standing; SP is the current formulation
PERpose PlusPeroxide-based broad-spectrum sanitizer and fungicide (analyst knowledge)GreenhousePre-2023
SandrineCopper soap fungicide and bactericideHorticulture and specialty cropsLaunched Feb 2026

Pest Control

ProductDescription and capabilityTarget customerLaunch / status
PRINCIPLE WPBroad-spectrum bioinsecticide based on Beauveria bassiana; developed in-house from grower feedback; replaces the BotaniGard/Mycotrol slot lost in 2022Greenhouse and specialty crops2,025
BioNexPest control product—Launched H1 2026
CintroInsecticidal soapHorticultureLaunched Feb 2026
EpiShield OPest control product—Listed 2026
Molt-XAzadirachtin-based insect growth regulator (analyst knowledge)Greenhouse, nurseryLong-standing
NemaShieldBeneficial nematodes, Steinernema feltiae, for fungus gnats and thrips pupae (analyst knowledge)GreenhousePre-2023
NemaShield HBBeneficial nematodes, Heterorhabditis bacteriophora, for soil grubs and weevils (analyst knowledge)Nursery, turfPre-2023
SuffOil-XPre-emulsified light horticultural oil for soft-bodied insects and mites, with suppression of some foliar diseasesGreenhouse, nurseryLong-standing
TotalNema AxFIFRA 25(b) botanical nematicide against plant-parasitic nematodesOutdoor specialty cropsLaunched 15 May 2026
Sticky CardsMonitoring and mass-trapping cardsGreenhouseAccessory

Herbicide

ProductDescriptionLaunch / status
HopliteBioWorks' first herbicide entryLaunched H1 2026

Plant Nutrition and Biostimulants

ProductDescriptionLaunch / status
ON-GardPlant-derived nutritional biostimulant (protein hydrolysate; analyst knowledge)In portfolio since at least 2015
R.S.S.I.Plant nutrition productListed 2026
GreenSpringMixed-mineral fertilizer for root initiation and early development; designed to fit IPM programsLaunched 10 Jul 2026
StemmerHighly soluble silicon product for cell wall strength, nutrient and water use efficiencyLaunched 4 Aug 2026
BioRain AxMicrobial inoculant to mitigate limited-water stress and support yieldLaunched 3 Sep 2026

Canada catalogue

The Canadian range is narrower because of separate PMRA registration: RootShield, MilStop, SuffOil-X and ON-Gard.

Discontinued or transferred

ProductStatus
BotaniGard (22WP, ES, MAXX) and Mycotrol (WPO, ESO)Distributed by BioWorks until September 2022; returned to manufacturer Certis Biologicals
Verdanta fertilizersIn portfolio in 2015–2018; absent from the 2026 catalogue
RootMate, TopShieldHistorical trademarks and labels; not in the current catalogue

Services

Technical services (program design, compatibility guidance with beneficial insects, webinars, a knowledge base and trial work) are provided free of charge as sales support. Named technical leaders include Dr. Michael Brownbridge (Senior Technical Services Manager) and Carlos E. Bográn (Director of Technical Services).

Financial Narrative

BioWorks, Inc. standalone. Revenue, gross profit, operating income, EBITDA, net income, balance sheet, cash flow and all ratios are not publicly disclosed. As an unlisted subsidiary it publishes no financial statements, and Floridienne does not break out BioWorks in its segment note. The acquisition price paid by Biobest in 2023 was also not disclosed. The only quantitative markers in the public record are:

Parent context: Floridienne S.A. consolidated (EUR millions, IFRS). Source: Annual Report 2025 five-year summary and annual results releases.

Revenue CAGR FY2021–FY2025: about 19.7% (calculated).

Parent context: Life Sciences Division, which contains BioFirst and BioWorks (EUR millions).

Half-year series, Life Sciences Division (EUR millions).

H1 2026 results would normally have been published in late September 2026.

Data flags.

  • Group EBITDA of EUR 116.8 million for FY2024 comes from a secondary source and was not confirmed against the filing. Group EBITDA for other years was not captured.

  • The FY2024 net result attributable to Floridienne appears as 16.07 in the FY2024 release and 15.7 in the Annual Report 2025 summary. Both are shown here; the later figure may reflect a restatement.

  • Earnings per share: the H1 2025 report shows basic EPS of EUR -6.48 (H1 2024: EUR 1.35). Test-Achats (June 2026) cites FY2025 EPS of EUR 0.81, which is inconsistent with a group-share result of EUR 8.0 million on the historical share count unless the share count changed.

  • No estimates are substituted.

Commentary. Three points matter for a reader interested in BioWorks.

First, the group that owns BioWorks changed shape in a single transaction. Life Sciences revenue rose 41.1% in FY2024 and EBITDA more than doubled, and almost all of that is BIOTROP's consolidation. The historical greenhouse business (Biobest, BioWorks, Plant Products) is described by Floridienne as performing well in 2024 on sustained demand and production efficiency, but it is now the smaller part of the division.

Second, profitability softened in 2025. Division EBITDA fell EUR 6.8 million to EUR 95.4 million despite higher sales, and the H1 2025 report attributes the first-half decline mainly to keener competition. Group net result halved, with Floridienne citing unfavourable currency trends; Test-Achats also points to higher amortization and Turkish hyperinflation accounting. A BRL-exposed, leveraged parent with compressing margins has less room to fund subsidiaries generously.

Third, 2023 was a weak year for Biobest's legacy business (Floridienne called it disappointing, citing external factors), which is the period in which BioWorks was acquired. BioWorks was bought into a trough and has since been run through a recovery and then a leadership change.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LevelEntityRole

Listed parent

Floridienne S.A. (Belgium)

Holding group with three divisions: Life Sciences, Food, Chemicals

Division

Life Sciences

Contains BioFirst Group and Natix (natural extracts for pharma and cosmetics)

Sub-group

BioFirst Group (legal entity Biobest Group NV)

Brands: Biobest, BioWorks, Plant Products, BIOTROP.

Platform

BIOTROP North America (created Aug 2026)

Combines BioWorks North America and BIOTROP USA; reports to Jonas Hipolito, President of BIOTROP

Subject

BioWorks, Inc.

Horticulture, greenhouse, ornamental and specialty crops

Results by Segment

Segment metric (EUR Mn)FY2023FY2024FY2025

Life Sciences revenue

359.4507.1538.3

Food revenue

146.6151.0155.2

Chemicals revenue

43.339.332.4

Group revenue

549.3697.3725.9

Life Sciences EBITDA

41.2102.395.4

Food EBITDA

8.111.011.1

Chemicals EBITDA

9.05.35.7

Life Sciences net result

8.127.713.3

Food net result

—4.15.4

Chemicals net result

—2.2-0.3

Segment Margins & Growth (%) and Revenue by Segment (%)

Derived metric (%)FY2023FY2024FY2025

Life Sciences EBITDA margin

11.520.217.7

Life Sciences revenue growth YoY

6.641.16.2

Life Sciences share of group revenue

65.472.774.2

Food EBITDA margin

5.57.37.2

Chemicals EBITDA margin

20.813.517.6

Bioworks Marker Details

BioWorks markerValueSource

Revenue growth 2010

27%

RBJ, 5 Jul 2013

Revenue growth 2011

23%

RBJ, 5 Jul 2013

Revenue growth 2012

10%

RBJ, 5 Jul 2013

Growth descriptor 2018

Double-digit annually

Western Growers profile

Revenue target 2034

USD 100 million

BIOTROP release, Aug 2026

Combined BIOTROP North America target 2034

More than USD 260 million

BIOTROP release, Aug 2026

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR Mn)

353.1518.3549.3697.3725.9

EBITDA (EUR Mn)

———116.8—

Consolidated net result (EUR Mn)

18.618.58.630.915.1

Net result, Floridienne share (EUR Mn)

13.212.03.615.78.0

Revenue growth YoY (%)

—46.86.026.94.1

Net margin (%)

5.33.61.64.42.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2022–FY2025)

MetricFY2022FY2023FY2024FY2025

Revenue (EUR Mn)

337.1359.4507.1538.3

EBITDA (EUR Mn)

47.841.2102.395.4

Net result (EUR Mn)

13.38.127.713.3

EBITDA margin (%)

14.211.520.217.7

Net margin (%)

3.92.35.52.5

Income Statement

MetricH1 2022H1 2023H1 2024H1 2025

Revenue (EUR Mn)

169.7185.7236.3259.5

EBITDA (EUR Mn)

—28.135.734.0

Net result (EUR Mn)

11.910.26.8-4.4

Region Overview

RegionPresenceEvidence

United States

Core market; full catalogue; national field team being expanded

Website; Feb 2026 release

Canada

Reduced four-product catalogue; distributor network

Website

Mexico

Distributor network

Website

Europe

BioWorks brand launched Sep 2025; distributors purchase directly from BioWorks

New AG International

Brazil

Destination for Trichoderma exports from Victor, announced Feb 2026

BioWorks release

Capital Markets

ItemStatus

Credit ratings (Moody's, S&P, Fitch)

None identified

Income Statement (Annual)

Chartable parent metricFY2021FY2022FY2023FY2024FY2025

Floridienne revenue (EUR Mn)

353.1518.3549.3697.3725.9

Floridienne net result, group share (EUR Mn)

13.212.03.615.78.0

Analyst Conclusions

Management guidance. There is no annual guidance. The stated targets are USD 100 million of BioWorks revenue and more than USD 260 million for the combined BIOTROP North America platform by 2034. Floridienne described the Life Sciences outlook as favourable in its FY2024 release; the FY2025 release notes currency and profitability pressure. Consensus expectations do not exist for BioWorks.

Bull case

  1. Pipeline step-change. Nine launches in 2026 against a historical base of about twenty products, with BIOTROP's technology behind them, widen the catalogue into nematicides, herbicides and nutrition.

  2. Manufacturing leverage. Exporting Trichoderma to Brazil and Europe turns Victor from a regional plant into a group supply node, improving fixed-cost absorption.

  3. Channel and brand. Thirty years of distributor relationships and technical trust in greenhouse horticulture are hard to replicate, and they now carry more products per call.

Bear case

  1. Parent constraints. Floridienne's FY2025 net result halved and H1 2025 was loss-making; investment in a small US subsidiary competes with a large Brazilian business for capital and attention.

  2. Execution load. A new platform head from outside, an interim GM, a new sales director and a rapid launch schedule arrive together.

  3. Competitive response. Certis, Koppert and the multinationals are all active in the same greenhouse accounts, and Floridienne itself cites tougher competition.

Catalysts and monitorables, next 12 months

  • The 90-day integrated North America strategy, due around November 2026.

  • Whether Chris Rose is confirmed as General Manager.

  • Floridienne H1 2026 and FY2026 results, especially Life Sciences EBITDA margin (17.7% in FY2025 against 20.2% in FY2024).

  • First evidence of Trichoderma export volumes.

  • EPA registrations of BIOTROP-origin products under the BioWorks label.

  • Completion of the remaining 15% BIOTROP purchase and how it is financed.

  • European registration progress under the new EMEA regulatory director.

It is a 33-year-old specialist that was sold in 2023 and now sits three levels below a Belgian listed holding company. That fact shapes everything an outside party can and cannot know about it. Its revenue, margins and headcount are undisclosed, and any figure presented for them elsewhere should be treated with suspicion.

What can be said with confidence is that the business is in the most active period of its history. Under Bill Foster it was a careful, self-funded company that found its niche in greenhouse horticulture after an early misjudgment about row crops. Under BioFirst and BIOTROP it is being asked to do something different: multiply its catalogue, sell into outdoor specialty crops, supply other continents from one New York plant, and reach USD 100 million of revenue by 2034. The 2026 launch record shows the pipeline is real. The loss of BotaniGard in 2022, and the recovery through PRINCIPLE WP, shows the organization can develop its own products when it has to.

The risks are mostly about ownership. The parent's earnings weakened in 2025, competition is intensifying, and the new North American structure places BioWorks under a leader recruited from Koppert with a mandate to integrate. The stated commitment to keep the brands and go-to-market separate is sensible, because BioWorks' value lies in grower trust and technical service, and neither survives a clumsy merger.

For a counterparty, supplier or competitor, the practical reading is this: BioWorks is a credible and growing channel into North American protected horticulture, with improving access to technology and capital, and with decisions increasingly made outside Victor. The November 2026 strategy output and the permanent GM appointment are the two events most likely to show which direction the company takes.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure and backgroundSource

Chris Rose

Interim General Manager, BioWorks (from 24 Feb 2026)

Biologist by training; with BioWorks since 2013; previously product manager

BioWorks release; Greenhouse Grower

Andre Cerignoni

General Manager, BIOTROP North America (from Aug 2026)

Oversees BioWorks North America and BIOTROP USA. Previously Marketing and Commercial Manager, US, at Koppert; over ten years at Koppert Brazil. MBAs from USP and FGV

BIOTROP release

Jonas Hipolito

President, BIOTROP

Cerignoni's reporting line

BIOTROP release

Matheus Gueratto

Head of BIOTROP USA

Built row-crop operation across 23 states with 13 registered products

BIOTROP release

Lara Ramaekers

Vice-President, BioWorks division (Europe launch)

—

New AG International

Jason Miller

Director of Sales and Distributor Relations Manager (from Feb 2026)

Leads North American sales strategy

BioWorks release

Carlos E. Bográn

Director of Technical Services

—

HortiDaily, Jul 2025

Dr. Michael Brownbridge

Senior Technical Services Manager

—

BioWorks articles

David Spampinato

Senior Product Manager; media contact

—

2B Monthly; releases

José Carvalho

Regulatory Director, BioWorks Europe

—

2B Monthly

Dr. Glen Stevens

R&D Associate (from Aug 2025)

Over two decades in biological control and soil health

BioWorks release

Bill Foster

Former President and CEO

Led the company for nearly three decades; stayed through end of May 2026 for transition

BioWorks release

Competitive Landscape

Key Competitors

CompetitorOwnerOverlap with BioWorksComparable revenue

Certis Biologicals

Mitsui & Co.

Closest direct rival in US greenhouse biopesticides; owns BotaniGard and Mycotrol

—

Koppert

Private (Netherlands)

Beneficials, microbials and Trichoderma products; source of BIOTROP NA's new GM

—

ProFarm Group (formerly Marrone Bio)

Bioceres Crop Solutions

Biofungicides and bioinsecticides in specialty crops

—

Valent BioSciences

Sumitomo Chemical

Bt products, biostimulants

Not disclosed separately

Bayer Crop Science (biologics)

Bayer AG

Serenade (QST 713) and others

Not disclosed separately

BASF (biologicals)

BASF SE

Beauveria products and beneficial nematodes

Not disclosed separately

Syngenta Biologicals

Syngenta Group

Biostimulants and biocontrols

Not disclosed separately

Lallemand Plant Care

Lallemand Inc. (private)

Microbial biofungicides

—

BioSafe Systems

Private (US)

Peroxide chemistries and biopesticides in greenhouse

—

OHP

AMVAC / American Vanguard

Greenhouse and nursery specialty products including biologicals

Not disclosed separately

SePRO

Private (US)

Greenhouse and nursery fungicides and biologicals

—

Andermatt Group

Private (Switzerland)

Microbials, expanding in North America

—

“—” = not publicly disclosed.

Competitor Detail

MetricBioWorks

Growth

Not disclosed (2034 target implies sustained double-digit growth)

Recent Developments

Entries slightly outside the window are included for context and marked.

AgroPages lists some of the 2026 items with dates a few days later than BioWorks' own releases; the BioWorks dates are used.

Company Snapshot

$818.4M

Revenue

950

Employees

1993

Founded

NY, US

Headquarters

SWOT Analysis

Strengths

  • Proprietary heritage technology: T-22 Trichoderma licensed from Cornell in 1993 and still the flagship in 2026.
  • Integrated site: more than 55,000 sq ft in Victor combining manufacturing, R&D and warehousing, designated the group's North American biopesticide hub.
  • Long record of growth as an independent: 27%, 23% and 10% in 2010–2012, and double-digit growth reported in 2018.
  • Demonstrated development capability: PRINCIPLE WP brought to market within about three years of losing BotaniGard.
  • Strong parent: BioFirst reports over USD 580 million in revenue, and Life Sciences EBITDA was EUR 95.4 million in FY2025.
  • Technical credibility: named specialists publish regularly in trade media, and the company has given more than USD 100,000 to AFE research and education.
  • Management continuity at operating level: the interim GM has been with the company since 2013.

Weaknesses

  • No financial transparency: no standalone revenue, margin or headcount is published.
  • Licensed-product exposure: CEASE depends on a third-party strain, and the BotaniGard precedent shows such arrangements can end.
  • Narrow Canadian range: four products against more than twenty in the US.
  • Leadership still interim eight months after February 2026.
  • Limited outdoor crop track record: the founders' original row-crop strategy was abandoned, and specialty agriculture remains an expansion target.
  • Channel dependence: sales run through distributors, with no disclosed direct accounts.

Opportunities

  • BIOTROP technology transfer: 13 products already registered in the US by BIOTROP USA, and a stated intent to use BIOTROP technologies through BioWorks.
  • Export manufacturing: Trichoderma shipments to Brazil and Europe would raise utilisation at Victor.
  • Europe: brand entry in September 2025 through Biobest's established grower relationships.
  • Plant nutrition adjacency: three launches in summer 2026 sold to the existing customer base.
  • Specialty crops: grapes, almonds and berries named as targets; TotalNema Ax launched for outdoor specialty use.
  • Shared regulatory and market intelligence functions under the new platform.

Threats

  • Parent financial pressure: Floridienne's net result fell from EUR 30.9 million to EUR 15.1 million in FY2025, with an H1 2025 net loss of EUR 8.2 million.
  • Competitive intensity: cited by Floridienne as the main cause of the H1 2025 EBITDA decline in Life Sciences.
  • Integration risk: a new management layer whose head joined from a competitor and has 90 days to design an operating model.
  • Loss of identity: the "platform, not a merger" language concedes the concern exists.
  • Currency: a group with over half its revenue linked to Brazil is exposed to BRL swings, which affected FY2025.
  • Launch overload: nine launches in eight months through a small field team risks thin support per product.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Nov 2024 (context)Libby Brallier joins as advisor, Pacific NorthwestField coverage
20 Nov 2024 (context)Bill Rietkerk joins as senior advisor to lead specialty agriculture expansionSignals outdoor crop push
31 Mar 2025Floridienne FY2024 results: record year, BIOTROP integratedParent strength
Jul 2025"Making the Move" article in GrowerTalks Biosolutions GuideThought leadership
14 Jul 2025PRINCIPLE WP reported as successfully entering the marketFills bioinsecticide gap
4 Aug 2025Dr. Glen Stevens joins R&DPest control R&D depth
Sep 2025Trichoderma article in HortiDailyTechnical positioning
19 Sep 2025BioWorks brand taken to EuropeNew geography
30 Sep 2025Floridienne H1 2025: division sales up 9.8%, EBITDA down, net lossParent margin pressure
11 Feb 2026Lifetime AFE contributions exceed USD 100,000Industry standing
12 Feb 2026Jason Miller appointed Director of Sales and Distributor Relations ManagerSales leadership
19 Feb 2026Sandrine copper soap launchedPortfolio breadth
19 Feb 2026Cintro insecticidal soap launchedPortfolio breadth
24 Feb 2026Chris Rose named Interim General ManagerEnd of the Foster era
24 Feb 2026*Trichoderma* exports from Victor to Brazil and Europe announcedSite becomes a global supply node
31 Mar 2026Floridienne FY2025 results: sales up, EBITDA and net result downParent margin pressure
–BioNex launchedNew pest control product
–Hoplite launchedFirst herbicide
–Michelle Opela joins as advisor, US SoutheastField coverage
–José Carvalho appointed Regulatory Director, BioWorks EuropeEMEA registrations
May 2026Digger Magazine feature on biofungicides in nurseriesNursery segment visibility
15 May 2026TotalNema Ax nematicide launchedOutdoor specialty crops
End May 2026Bill Foster's transition period endsLeadership handover complete
Jun 2026"Biofungicides and Biostimulants" technical articleCross-selling nutrition with protection
10 Jul 2026GreenSpring fertilizer launchedPlant nutrition line
4 Aug 2026Stemmer silicon product launchedPlant nutrition line
Aug 2026Andre Cerignoni named GM, BIOTROP North America; 2034 targets publishedNew reporting layer and public targets
Aug 2026RootShield PLUS boxwood trial with Everde Growers publishedNursery evidence base
3 Sep 2026BioRain Ax microbial inoculant launchedAbiotic stress category

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (%): Life Sciences share of group revenue rose from 65.4% in FY2023 to 74.2% in FY2025.
BioWorks Inc. — Revenue by Segment (%)
Series (%)FY2023FY2024FY2025
Life Sciences share of group revenue65.472.774.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BioWorks, Inc. website and press releases (bioworksinc.com), 2024–2026
  2. Biobest Group press releases, 4 May 2023 and 10 July 2023
  3. BIOTROP press release on North America leadership, August 2026
  4. Floridienne S.A.: FY2023, FY2024 and FY2025 results releases; half-year reports 2023, 2024 and 2025; Annual Reports 2023 and 2025
  5. Rochester Business Journal, 5 July 2013
  6. American Phytopathological Society, Fellow profile of Gary E. Harman
  7. Western Growers Association sponsor profile, 2018
  8. Greenhouse Canada, 12 August 2015
  9. New AG International, 19 September 2025
  10. Nursery Management, Greenhouse Grower, Greenhouse Management, HortiDaily, Vegetable Growers News, AgroPages, 2B Monthly (2017–2026)
  11. La Libre, 7 September 2023
  12. Test-Achats Invest, June 2026
  13. USPTO trademark records via Justia

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.